Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. License Agreement By and Between Amgen Inc. and Takeda...License Agreement • May 12th, 2008 • Amgen Inc • Biological products, (no disgnostic substances) • California
This License Agreement (this “Agreement”) is entered into as of the 1st day of February, 2008 (the “Effective Date”) by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (“Amgen”), and Takeda Pharmaceutical Company Limited, a Japanese corporation having its principal place of business at 1-1, Doshomachi 4-Chome, Chuo-ku, Osaka 540-8645, Japan (“Licensee”). Amgen and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. License Agreement By and Between Amgen Inc. and Takeda...License Agreement • May 12th, 2008 • Amgen Inc • Biological products, (no disgnostic substances) • California
This License Agreement (this “Agreement”) is entered into as of the 1st day of February, 2008 (the “Effective Date”) by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, U.S.A. (“Amgen”), and Takeda Pharmaceutical Company Limited, a Japanese corporation having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Licensee”). Amgen and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. SALE AND PURCHASE AGREEMENT by and between AMGEN INC. and...Sale and Purchase Agreement • May 12th, 2008 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This Sale and Purchase Agreement (including its Exhibits and Schedules, this “Agreement”) is entered into as of February 1, 2008 by and between Amgen Inc., a Delaware corporation (“Seller”), and Takeda Pharmaceutical Company Limited, a Japanese corporation (“Buyer”). Seller and Buyer are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. Supply Agreement by and between Amgen Inc. and Takeda...Supply Agreement • May 12th, 2008 • Amgen Inc • Biological products, (no disgnostic substances) • California
This Supply Agreement (this “Agreement”) is entered into as of the 1st day of February, 2008 (the “Effective Date”) by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, U.S.A. (“Amgen”), and Takeda Pharmaceutical Company Limited, a Japanese corporation having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Purchaser”). Amgen and Purchaser are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
